These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36751113)

  • 1. Dual-targeting therapy against HER3/MET in human colorectal cancers.
    Yamasaki A; Miyake R; Hara Y; Okuno H; Imaida T; Okita K; Okazaki S; Akiyama Y; Hirotani K; Endo Y; Masuko K; Masuko T; Tomioka Y
    Cancer Med; 2023 Apr; 12(8):9684-9696. PubMed ID: 36751113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.
    De Boeck A; Pauwels P; Hensen K; Rummens JL; Westbroek W; Hendrix A; Maynard D; Denys H; Lambein K; Braems G; Gespach C; Bracke M; De Wever O
    Gut; 2013 Apr; 62(4):550-60. PubMed ID: 22535374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-346-5p promotes colorectal cancer cell proliferation in vitro and in vivo by targeting FBXL2 and activating the β-catenin signaling pathway.
    Pan S; Wu W; Ren F; Li L; Li Y; Li W; Wang A; Liu D; Dong Y
    Life Sci; 2020 Mar; 244():117300. PubMed ID: 31953162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
    Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
    Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
    Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
    J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Met receptor pathway in aggressive behavior of colorectal cancer cells induced by parathyroid hormone-related peptide.
    Novoa Díaz MB; Carriere P; Gigola G; Zwenger AO; Calvo N; Gentili C
    World J Gastroenterol; 2022 Jul; 28(26):3177-3200. PubMed ID: 36051345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.
    Uddin S; Ahmed M; Hussain A; Abubaker J; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Jehan Z; Bavi P; Siraj AK; Al-Kuraya KS
    Am J Pathol; 2011 Feb; 178(2):537-47. PubMed ID: 21281787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
    Uddin S; Hussain AR; Ahmed M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
    Am J Pathol; 2011 Dec; 179(6):3032-44. PubMed ID: 21978492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIM6 promotes colorectal cancer cells proliferation and response to thiostrepton by TIS21/FoxM1.
    Zheng S; Zhou C; Wang Y; Li H; Sun Y; Shen Z
    J Exp Clin Cancer Res; 2020 Jan; 39(1):23. PubMed ID: 31992359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short hairpin RNA- mediated gene knockdown of FOXM1 inhibits the proliferation and metastasis of human colon cancer cells through reversal of epithelial-to-mesenchymal transformation.
    Yang K; Jiang L; Hu Y; Yu J; Chen H; Yao Y; Zhu X
    J Exp Clin Cancer Res; 2015 May; 34(1):40. PubMed ID: 25935853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
    Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
    Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
    Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
    Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
    Zhang Y; Li KF
    Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.